PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

REDUCE-1 Pilot: Restrictive Fluids Safe But Failed Feasibility in PICU

restrictive fluid strategyintravenous fluidsfluid overloadpediatric critical carePICUmechanical ventilationREDUCE-1pilot RCTvasoactive-inotrope scoreacute kidney injuryfeasibility trial Critical Care / ICU
Also in Pediatrics

Background Information

Can restrictive fluid protocols improve outcomes in PICU patients?

Fluid management in pediatric intensive care unit (PICU) patients is crucial due to the risks associated with fluid overload, impacting outcomes. The study demonstrated that a restrictive intravenous (IV) fluid strategy did not achieve a significant difference in fluid balance compared to usual care in mechanically ventilated children. The REDUCE-1 restrictive fluid protocol as tested in this pilot study is not feasible for a full trial, hence future studies need refined protocols. Restrictive fluid management in PICU requires further refinement for feasibility.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Raman S, Rahiman S, Kennedy M, Kühlwein E, Le Marsney R, Mattke AC, McBride CA, Tu Q, Venugopal P, Woodgate J, Zapf F, Singh P, Schlapbach LJ, Gibbons KS

Citation: Raman S, Rahiman S, Kennedy M, et al. REstrictive versus StandarD FlUid Management in Mechanically Ventilated ChildrEn Admitted to PICU: a pilot randomized controlled trial (REDUCE-1). Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2026;27(8):998-1010. doi:10.1097/PCC.0000000000003969

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.